Did you ever wonder why Pfizer very suddenly withdrew their vaccine application to regulatory bodies in India? Now might be a good time to take a look into a story that was promptly killed, disemboweled, drawn, quartered, and buried under a swamp for a year. Pfizer pulled back their application for an emergency-use authorization in India, similar to that which they hold in the US for their COVID ‘vaccine’ after Indian regulators threw one hell of a curveball at them. India’s regulators require a “local safety and immunogenicity study” according to The Gateway Pundit and Reuters. The most important question to come from this is… why didn’t we?
The local trial, GP reports is a “standard procedure imposed in India when a new vaccine is available to determine its safety and generate an immune response in its citizens.” It seems simple enough, doesn’t it? 1.) Is it safe? 2.) Does it actually generate immunity? So why was Pfizer so very afraid of submitting to this testing? Could it be that they knew from the start… that it would fail?
Reuters reported,
“Unlike other companies conducting small studies in India for foreign-developed vaccines, Pfizer had sought an exception citing approvals it had received elsewhere based on trials done in countries such as the United States and Germany.
Indian health officials say they generally ask for so-called bridging trials to determine if a vaccine is safe and generates an immune response in its citizens. There are, however, provisions under India’s rules to waive such trials in certain conditions.”
Pfizer Couldn’t Meet India’s Scrutiny
The Indian Express, however, didn’t mince words, “The Subject Expert Committee under CDSCO (Central Drugs Standard Control Organization) that looked into Pfizer’s proposal and presentation did not recommend that the Drug Controller General of India (DCGI) approve the application at present.”
The Express reported on the Subject Expert Committee under CDSCO’s serious concerns.
- “The committee noted that incidents of palsy, anaphylaxis and other SAE’s have been reported during post-marketing and the causality of the events with the vaccine is being investigated. Further, the firm has not proposed any plan to generate safety and immunogenicity data in Indian population,”
- SAE’s or Serious Adverse Events and ” the fact that additional safety information had not been generated from local trials in the country.
This advisory decision caused the Committee to recommend against approval, prompting Pfizer to withdraw the request.
“Based on the deliberations at the meeting and our understanding of additional information that the regulator may need, the company has decided to withdraw its application at this time,” stated a Pfizer spokesperson.
The question rings very loudly and demands an answer: If the authorities in New Dehli weren’t convinced by the science, then what convinced Washington, D.C.?
